Replication Study to Analyze the Surgical Treatment of Proximal Humeral Fracture (NCT06537024) | Clinical Trial Compass
CompletedNot Applicable
Replication Study to Analyze the Surgical Treatment of Proximal Humeral Fracture
32,953 participantsStarted 2011-01-01
Plain-language summary
The study at hand aimed to analyze the replicability of the observed treatment effects in these studies published by Koeppe et al. and Stolberg-Stolberg et al.
Who can participate
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
\- all patients will be included, who had an inpatient coded treatment using LPF or RTSA
Exclusion Criteria:
* Incomplete insurance status within two years before index
* Incomplete basic information
* Age\<65 years
* Missing diagnosis of PHF (ICD: S42.2) within two years before surgery
* Previous surgical treatment (RTSA, LPF or other fracture fixation)
* Coded polytrauma
* Bone tumors/ bone metastasis
* Both sides or missing information of surgery side
* COVID-19 infection during index hospitalization
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
30-day mortality
Timeframe: 30 days
2
Overall survival (OS)
Timeframe: up to 12 years
3
Major adverse events during index case
Timeframe: through hospital stay, an average of 16 days
4
Major adverse events after discharge
Timeframe: up to 12 years
5
Thromboembolic events during index
Timeframe: through hospital stay, an average of 16 days
6
Thromboembolic events (or death) after discharge
Timeframe: up to 12 years
7
Surgical complications during index case
Timeframe: through hospital stay, an average of 16 days